[go: up one dir, main page]

DE60003860D1 - Peptide, die anti-Zellanhaftungsaktivität aufweisen - Google Patents

Peptide, die anti-Zellanhaftungsaktivität aufweisen

Info

Publication number
DE60003860D1
DE60003860D1 DE60003860T DE60003860T DE60003860D1 DE 60003860 D1 DE60003860 D1 DE 60003860D1 DE 60003860 T DE60003860 T DE 60003860T DE 60003860 T DE60003860 T DE 60003860T DE 60003860 D1 DE60003860 D1 DE 60003860D1
Authority
DE
Germany
Prior art keywords
ala
peptides
cell attachment
amino acid
inhibitory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003860T
Other languages
English (en)
Other versions
DE60003860T2 (de
Inventor
Katsuhiko Akiyama
Takeshi Goto
Fumio Fukai
Masaaki Ueki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Publication of DE60003860D1 publication Critical patent/DE60003860D1/de
Application granted granted Critical
Publication of DE60003860T2 publication Critical patent/DE60003860T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60003860T 1999-03-16 2000-03-16 Peptide, die anti-Zellanhaftungsaktivität aufweisen Expired - Fee Related DE60003860T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11070127A JP2000264900A (ja) 1999-03-16 1999-03-16 新規生理活性ペプチド
JP7012799 1999-03-16

Publications (2)

Publication Number Publication Date
DE60003860D1 true DE60003860D1 (de) 2003-08-21
DE60003860T2 DE60003860T2 (de) 2004-02-05

Family

ID=13422589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003860T Expired - Fee Related DE60003860T2 (de) 1999-03-16 2000-03-16 Peptide, die anti-Zellanhaftungsaktivität aufweisen

Country Status (5)

Country Link
US (1) US6451971B1 (de)
EP (1) EP1036798B1 (de)
JP (1) JP2000264900A (de)
AT (1) ATE245168T1 (de)
DE (1) DE60003860T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601511B2 (en) 2003-11-12 2009-10-13 University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382031D1 (en) * 1982-08-04 1991-01-10 Jolla Cancer Res Found Polypeptide.

Also Published As

Publication number Publication date
EP1036798A1 (de) 2000-09-20
JP2000264900A (ja) 2000-09-26
EP1036798B1 (de) 2003-07-16
US6451971B1 (en) 2002-09-17
ATE245168T1 (de) 2003-08-15
DE60003860T2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
ATE477020T1 (de) Prevention und verringerung von ischemia
DE60329201D1 (de) Substituierte wt1-peptide
ATE332922T1 (de) Antimikrobiell wirkendes peptid
EP0528312A3 (de) Zyklische Peptide und ihre Verwendung
EP0333356A3 (de) Hirudin-Peptide
ATE368053T1 (de) Antimikrobielle peptide
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
DE60003860D1 (de) Peptide, die anti-Zellanhaftungsaktivität aufweisen
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
MXPA06014393A (es) Peptidos oligomericos y su uso para el tratamiento de infecciones por vih.
CA2196308A1 (en) Peptide, bronchodilator and blood flow ameliorant
GB0210783D0 (en) Anti-microbial polypeptides
ATE42308T1 (de) Pharmakologisch aktive peptide.
ATE82984T1 (de) Hemmende peptide.
ATE140234T1 (de) Neue inhibitorische peptide
DE60038310D1 (de) Menschliche antithrombin-varianten
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
AU773969C (en) Novel tachykinin peptides, precursor peptides thereof and genes encoding the same
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
DE60325227D1 (de)
WO2003048187A3 (en) Peptides and use thereof in therapeutic agents against hiv infection
CA2030795A1 (en) Novel physiologically active peptide and calcium metabolism-regulating agent comprising said peptide as effective ingredient
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น
RU97114945A (ru) Белки против ожирения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee